Organogenesis Holdings Inc
For the period ended Mar 31, 2024. Filed May 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 9, 2024
ORGO$0.94+3.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
(amounts in thousands, except share data)
| Additional | |||||
|---|---|---|---|---|---|
| Common Stock · Paid-in · Accumulated · Total | |||||
| Shares | Amount | Capital | Deficit | Stockholders’ Equity | |
| Balance as of December 31, 2023 | 131,316,396 | $13 | $319,621 | $(40,971) | $278,663 |
| Exercise of stock options | 152,250 | — | 180 | — | 180 |
| Vesting of RSUs, net of shares surrendered to pay taxes | 1,070,694 | — | (1,120) | — | (1,120) |
| Stock-based compensation expense | — | — | 2,407 | — | 2,407 |
| Net loss | — | — | — | (2,100) | (2,100) |
| Balance as of March 31, 2024 | 132,539,340 | $13 | $321,088 | $(43,071) | $278,030 |
| Additional | |||||
|---|---|---|---|---|---|
| Common Stock · Paid-in · Accumulated · Total | |||||
| Shares | Amount | Capital | Deficit | Stockholders’ Equity | |
| Balance as of December 31, 2022 | 130,919,129 | $13 | $310,957 | $(45,301) | $265,669 |
| Cumulative-effect adjustment from adoption of ASU 2016-13, net of tax (Note 2) | — | — | — | (615) | (615) |
| Vesting of RSUs, net of shares surrendered to pay taxes | 307,258 | — | (298) | — | (298) |
| Stock-based compensation expense | — | — | 1,914 | — | 1,914 |
| Net loss | — | — | — | (2,969) | (2,969) |
| Balance as of March 31, 2023 | 131,226,387 | $13 | $312,573 | $(48,885) | $263,701 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.